Here’s the blurb
|
With research showing that psychedelics hold substantial promise for the treatment of mental health conditions such as depression, PTSD and addiction, PSYCH Symposium provides a platform for decision makers to accelerate the development and delivery of these medicines. This year’s event will explore the latest in psychedelic research and policy – looking in detail at the realistic time frames needed to make psychedelic healthcare mainstream, unique hurdles faced by the industry, frameworks researchers need to work within, and how the EU can help drive Europe to become a genuine global leader in psychedelic healthcare. PSYCH Symposium: London 2023 has now announced its first round of speakers from across policy, science and business, who will be joining together to help shape the future of psychedelic healthcare in Europe and highlight opportunities created by the very latest psychedelic research. |
 |
MIKULÁŠ PEKSAMEP European Parliament |
 |
DR DAVID ERRITZOEClinical Senior Lecturer & Consultant Psychiatrist Imperial College London |
 |
PROF. ALLAN YOUNGDirector CfAD, Institute Of Psychiatry, Psychology And Neuroscience Kings College London |
 |
AMIR INAMDARChief Medical Officer Cybin Inc. |
 |
NATAN PONIEMANEditor Benzinga |
 |
DR. CATHERINE SCHUSTER-BRUCEHealth Reporter Business Insider |
 |
TADEUSZ HAWROTFounder & Executive Director PAREA |
.jpg?width=520&upscale=true&name=Untitled%20design%20(21).jpg) |
PROF. CELIA MORGANHead Of Ketamine Assisted Psychotherapy For Addiction Awakn Life Sciences |
